Your browser doesn't support javascript.
loading
Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine.
Loomis, Rebecca J; DiPiazza, Anthony T; Falcone, Samantha; Ruckwardt, Tracy J; Morabito, Kaitlyn M; Abiona, Olubukola M; Chang, Lauren A; Caringal, Ria T; Presnyak, Vladimir; Narayanan, Elisabeth; Tsybovsky, Yaroslav; Nair, Deepika; Hutchinson, Geoffrey B; Stewart-Jones, Guillaume B E; Kueltzo, Lisa A; Himansu, Sunny; Mascola, John R; Carfi, Andrea; Graham, Barney S.
Afiliación
  • Loomis RJ; Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
  • DiPiazza AT; Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
  • Falcone S; Moderna Inc., Cambridge, MA, United States.
  • Ruckwardt TJ; Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
  • Morabito KM; Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
  • Abiona OM; Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
  • Chang LA; Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
  • Caringal RT; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
  • Presnyak V; Moderna Inc., Cambridge, MA, United States.
  • Narayanan E; Moderna Inc., Cambridge, MA, United States.
  • Tsybovsky Y; Vaccine Research Center Electron Microscopy Unit, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
  • Nair D; Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
  • Hutchinson GB; Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
  • Stewart-Jones GBE; Virology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
  • Kueltzo LA; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
  • Himansu S; Moderna Inc., Cambridge, MA, United States.
  • Mascola JR; Virology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
  • Carfi A; Moderna Inc., Cambridge, MA, United States.
  • Graham BS; Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Front Immunol ; 12: 772864, 2021.
Article en En | MEDLINE | ID: mdl-34956199
ABSTRACT
Nipah virus (NiV) represents a significant pandemic threat with zoonotic transmission from bats-to-humans with almost annual regional outbreaks characterized by documented human-to-human transmission and high fatality rates. Currently, no vaccine against NiV has been approved. Structure-based design and protein engineering principles were applied to stabilize the fusion (F) protein in its prefusion trimeric conformation (pre-F) to improve expression and increase immunogenicity. We covalently linked the stabilized pre-F through trimerization domains at the C-terminus to three attachment protein (G) monomers, forming a chimeric design. These studies detailed here focus on mRNA delivery of NiV immunogens in mice, assessment of mRNA immunogen-specific design elements and their effects on humoral and cellular immunogenicity. The pre-F/G chimera elicited a strong neutralizing antibody response and a superior NiV-specific Tfh and other effector T cell response compared to G alone across both the mRNA and protein platforms. These findings enabled final candidate selection of pre-F/G Fd for clinical development.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas Virales / Proteínas del Envoltorio Viral / Proteínas Virales de Fusión / Virus Nipah / Nanopartículas / Vacunas de ARNm / Liposomas / Antígenos Virales Límite: Animals Idioma: En Revista: Front Immunol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas Virales / Proteínas del Envoltorio Viral / Proteínas Virales de Fusión / Virus Nipah / Nanopartículas / Vacunas de ARNm / Liposomas / Antígenos Virales Límite: Animals Idioma: En Revista: Front Immunol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos